GSK3B and breast carcinoma: Our finding that HNK modulates Akt, GSK3β, and β-catenin, key components of leptin-signaling network in breast cancer cells, prompted us to further explore whether HNK treatment can also inhibit MTA1, Wnt1, β-catenin and cyclin D1 in the presence of leptin.